The partnership with Diagens to commercialize a new cytogenetic analysis tool that combines OGM and AI is likely to be viewed positively by the market. This collaboration not only enhances Bionano's product portfolio but also positions the company at the forefront of technological innovation in cytogenetic testing. Given the growing demand for advanced diagnostic solutions, this move could lead to increased adoption of Bionano's technologies, potentially driving up its stock price in the short term.